Objective: To evaluate the prognostic potential of expression levels of miR-200 family members (miR-200a, miR-200b, miR-200c, miR-429, miR-141) in plasma and exosomes from the tumor-draining vein (mesenteric vein [MV]) and peripheral vein (PV) of colon cancer (CC) patients. Methods: We analyzed the expression of miR-200 family members in matched samples of MV and PV plasma from 50 resected patients with CC and correlated our findings with overall survival (OS). We also examined the content of these microRNAs in MV and PV exosomes. Results: Expression levels were higher in MV than in PV (miR-200a, p < 0.001; miR-200b, p < 0.001; miR-429, p = 0.01; miR-200c, p = 0.05; miR-141, p = 0.05). Low levels of both miR-200c and miR-141 in MV plasma were associated with longer OS (p = 0.02). This association was maintained for the MV exosome cargo of miR-200c and miR-141 (p = 0.02). Conclusion: Our findings provide the first indication that expression levels of miR-200c and miR-141 in MV plasma can identify CC patients with poor prognosis. In addition, our results lend further support to the premise that tumor-draining veins constitute a better source of biomarkers than do PVs.

Keywords:
Colon cancer, Exosomes, Tumor-draining vein, miR-141, miR-200c
1.
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252–271.
2.
Pourhoseingholi MA: Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol 2012; 4: 68–70.
3.
Group QC: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020–2029.
4.
Sourvinou IS, Markou A, Lianidou ES: Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn 2013; 15: 827–834.
5.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997–1006.
6.
Schwarzenbach H, Nishida N, Calin GA, Pantel K: Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014; 11: 145–156.
7.
Allegra A, Alonci A, Campo S, Penna G, -Petrungaro A, Gerace D, Musolino C: Circulating microRNAs: new biomarkers in -diagnosis, prognosis and treatment of cancer (review). Int J Oncol 2012; 41: 1897–1912.
8.
Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011; 6: e17745.
9.
Yu DC, Li QG, Ding XW, Ding YT: Circulating microRNAs: potential biomarkers for cancer. Int J Mol Sci 2011; 12: 2055–2063.
10.
Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18: 883–891.
11.
Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O: Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009; 11: 1143–1149.
12.
Roberts CT, Kurre P: Vesicle trafficking and RNA transfer add complexity and connectivity to cell-cell communication. Cancer Res 2013; 73: 3200–3205.
13.
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108: 5003–5008.
14.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008; 105: 10513–10518.
15.
Li Y, Jiang Z, Xu L, Yao H, Guo J, Ding X: Stability analysis of liver cancer-related microRNAs. Acta Biochim Biophys Sin (Shanghai) 2011; 43: 69–78.
16.
Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash A, Alajez NM: microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep 2016; 6: 2599.
17.
Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM: Exosome mediated communication within the tumor microenvironment. J Control Release 2015; 219: 278–294.
18.
O’Driscoll L: Expanding on exosomes and ectosomes in cancer. N Engl J Med 2015; 372: 2359–2362.
19.
Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Mark MT, Molina H, Kohsaka S, Di Giannatale A, Ceder S: Tumour exosome integrins determine organotropic metastasis. Nature 2015; 527: 329–335.
20.
Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A: Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 2014; 259: 735–743.
21.
Chen J, Wang W, Zhang Y, Chen Y, Hu T: Predicting distant metastasis and chemoresistance using plasma miRNAs. Med Oncol 2014; 31: 799.
22.
Diaz T, Tejero R, Moreno I, Ferrer G, Cordeiro A, Artells R, Navarro A, Hernandez R, Tapia G, Monzo M: Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J Surg Oncol 2014; 109: 676–683.
23.
Feng X, Wang Z, Fillmore R, Xi Y: MiR-200, a new star miRNA in human cancer. Cancer Lett 2014; 344: 166–173.
24.
Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128: 1327–1334.
25.
Aydoğdu E, Katchy A, Tsouko E, Lin C-Y, Haldosén L-A, Helguero L, Williams C: MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis 2012; 33: 1502–1511.
26.
Castilla MÁ, Díaz-Martín J, Sarrió D, Romero-Pérez L, López-García MÁ, Vieites B, Biscuola M, Ramiro-Fuentes S, Isacke CM, Palacios J: MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One 2012; 7:e47709.
27.
Gravgaard KH, Lyng MB, Laenkholm A-V, Søkilde R, Nielsen BS, Litman T, Ditzel HJ: The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat 2012; 134: 207–217.
28.
Hur K, Takahashi M, Balaguer F, Nagasaka T, Hemmi H, Koi M, Boland CR, Goel A: MicroRNA-200c/141 cluster as a control switch between epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in human colorectal cancer metastasis. Gastroenterology 2011; 140:S–817.
29.
Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ: Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 2013; 15: 180–191.
30.
Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, Si J: Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009; 44: 556–561.
31.
Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y, Baba H: MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol 2012; 19(suppl 3): S656–S664.
32.
Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M: Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res 2010; 70: 4719–4727.
33.
Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-Tajes J, Quindós M: Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012; 10: 186.
34.
Pacurari M, Addison JB, Bondalapati N, Wan Y-W, Luo D, Qian Y, Castranova V, Ivanov AV, Guo NL: The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol 2013; 43: 548–560.
35.
Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH, Zhang YK: High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012; 29: 618–626.
36.
Monzo M, Martinez-Rodenas F, Moreno I, Navarro A, Santasusagna S, Macias I, Munoz C, Tejero R, Hernandez R: Differential MIR-21 expression in plasma from mesenteric versus peripheral veins: an observational study of disease-free survival in surgically resected colon cancer patients. Medicine (Baltimore) 2015; 94:e145.
37.
Monzo M, Santasusagna S, Moreno I, Martinez F, Hernández R, Muñoz C, Castellano JJ, Moreno J, Navarro A: Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer. Oncotarget 2017; 8: 30859–30869.
38.
Ruiz-Martinez M, Navarro A, Marrades RM, Viñolas N, Santasusagna S, Muñoz C, Ramírez J, Molins L, Monzo M: YKT6 expression, exosome release, and survival in non-small cell lung cancer. Oncotarget 2016; 7: 51515–51524.
39.
Monzo M, Santasusagna S, Moreno I, Martinez F, Hernáez R, Muñoz C, Castellano JJ, Moreno J, Navarro A: Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer. Oncotarget 2017; 8: 30859–30869.
40.
Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, Denkert C: Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012; 7:e51862.
41.
Rana S, Malinowska K, Zöller M: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013; 15: 281–295.
42.
Sceneay J, Smyth MJ, Möller A: The pre-metastatic niche: finding common ground. Cancer Metastasis Rev 2013; 32: 449–464.
43.
Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239–252.
44.
Pigati L, Yaddanapudi SC, Iyengar R, Kim D-J, Hearn SA, Danforth D, Hastings ML, Duelli DM: Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010; 5:e13515.
45.
Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S: Plasma miR-21:a potential diagnostic marker of colorectal cancer. Ann Surg 2012; 256: 544–551.
46.
Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D: Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 2016; 30: 836–848.
47.
Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano Y: Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer 2015; 113: 275–281.
48.
Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H: Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 2014; 9:e92921.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.